Pharmagene says profitability is a realistic objective
Pharmagene has reported a near-doubling in turnover in the first half of this year, on the back of strong growth in its drug discovery services division.
Archives for August 4, 2003
GPC says anti-MHC antibody is nearing clinic
GPC reports progress with its anti-MHC class II antibody, with potential in a range of haematological malignancies, and says it now has sufficient quantities to start a clinical trials programme.
Qiagen sales accelerate on new product lines
Qiagen has reported strong growth in sales and profits in the second quarter as last year's acquisitions of GenoVision and Xeragon start to exert their effects. The company has also signed two new deals in the area of RNA interference.
Dharmacon gets US RNAi patent
Dharmacon has been awarded a US Patent (No 6,590,093) which covers its proprietary 2'-ACE chemistry for the production of synthetic RNA oligonucleotides.
Takeda strikes deals to boost pipeline
Takeda signs two new research collaborations in the areas of Alzheimer's disease and antibody-based drugs, in a move to bolster its product pipeline.